South Korea · Delayed Price · Currency is KRW Curocell Statistics
Total Valuation
Curocell has a market cap or net worth of KRW 574.49 billion. The enterprise value is 596.29 billion.
| Market Cap | 574.49B |
| Enterprise Value | 596.29B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Curocell has 14.38 million shares outstanding. The number of shares has increased by 19.85% in one year.
| Current Share Class | 14.38M |
| Shares Outstanding | 14.38M |
| Shares Change (YoY) | +19.85% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 33.88% |
| Owned by Institutions (%) | 10.33% |
| Float | 9.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 19.56 |
| P/TBV Ratio | 21.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.12 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -19.15 |
Financial Position
The company has a current ratio of 0.44, with a Debt / Equity ratio of 1.72.
| Current Ratio | 0.44 |
| Quick Ratio | 0.39 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.62 |
| Interest Coverage | -12.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -101.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Curocell has paid 1.10 million in taxes.
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.18% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +30.18% |
| 50-Day Moving Average | 38,311.00 |
| 200-Day Moving Average | 31,637.75 |
| Relative Strength Index (RSI) | 48.22 |
| Average Volume (20 Days) | 82,517 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -20.14M |
| Operating Income | -38.47B |
| Pretax Income | -39.44B |
| Net Income | -39.44B |
| EBITDA | -32.31B |
| EBIT | -38.47B |
| Earnings Per Share (EPS) | -2,780.89 |
Balance Sheet
The company has 28.62 billion in cash and 50.42 billion in debt, giving a net cash position of -21.80 billion or -1,515.96 per share.
| Cash & Cash Equivalents | 28.62B |
| Total Debt | 50.42B |
| Net Cash | -21.80B |
| Net Cash Per Share | -1,515.96 |
| Equity (Book Value) | 29.37B |
| Book Value Per Share | 2,050.81 |
| Working Capital | -41.16B |
Cash Flow
In the last 12 months, operating cash flow was -31.08 billion and capital expenditures -57.72 million, giving a free cash flow of -31.14 billion.
| Operating Cash Flow | -31.08B |
| Capital Expenditures | -57.72M |
| Free Cash Flow | -31.14B |
| FCF Per Share | -2,165.31 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Curocell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.85% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.86% |
| FCF Yield | -5.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |